Stefan Kloiber
A5047723483- Tryptophan and brain disorders
- Treatment of Major Depression
- Stress Responses and Cortisol
- Bipolar Disorder and Treatment
- Genetic Associations and Epidemiology
- Cannabis and Cannabinoid Research
- Diet and metabolism studies
- Child and Adolescent Psychosocial and Emotional Development
- Functional Brain Connectivity Studies
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Genetics and Neurodevelopmental Disorders
- Mental Health Research Topics
- Epigenetics and DNA Methylation
- Birth, Development, and Health
- Neurotransmitter Receptor Influence on Behavior
- Cognitive Abilities and Testing
- Neuroscience and Neuropharmacology Research
- Neuroendocrine regulation and behavior
- Autism Spectrum Disorder Research
- Complementary and Alternative Medicine Studies
- Suicide and Self-Harm Studies
- Adolescent and Pediatric Healthcare
- Pharmacogenetics and Drug Metabolism
- Schizophrenia research and treatment
- Cardiovascular Disease and Adiposity
Centre for Addiction and Mental Health
2017-2025
University of Toronto
2017-2025
Mental Health Research Institute
2020-2024
Max Planck Institute of Psychiatry
2014-2023
University of Utah
2023
Virginia Commonwealth University
2019-2023
Huntsman (United States)
2023
Mental Health Research Canada
2020-2023
Canada Research Chairs
2023
Massachusetts General Hospital
2019
Mood and anxiety disorders are considered stress-related diseases characterized by an impaired function of mineralocorticoid glucocorticoid receptors (MR GR, respectively), the major regulatory elements hypothalamus-pituitary-adrenocortical (HPA) axis. A number so-called chaperone proteins moderate these receptors. Genetic variations in one chaperones, FKBP5, were associated with antidepressant treatment response depression a risk-factor for development posttraumatic stress disorder. To...
Context:The efficacy of antidepressant drug treatment in depression is unsatisfactory; 1 3 patients does not fully recover even after several trials.Genetic factors and clinical characteristics contribute to the failure a favorable outcome.Objective: To identify genetic determinants outcome depression.Design: Genomewide pharmacogenetic association study with 2 independent replication samples.Setting: We performed genomewide from Munich Antidepressant Response Signature (MARS) project pooled...
Abstract Borderline personality disorder (BOR) is determined by environmental and genetic factors, characterized affective instability impulsivity, diagnostic symptoms also observed in manic phases of bipolar (BIP). Up to 20% BIP patients show comorbidity with BOR. This report describes the first case–control genome-wide association study (GWAS) BOR, performed one largest BOR patient samples worldwide. The focus our analysis was (i) detect genes gene sets involved (ii) investigate overlap...
Depression has frequently been reported to be associated with other physical diseases and changes in the cytokine system. We aimed investigate associations between a medical history of depression, its comorbidities plasma levels Bavarian Nutrition Survey II (BVS II) study sample patients suffering from an acute depressive episode. The BVS is representative population aged 13-80years. disease 1050 participants was assessed through face-to-face interviews. A sub-sample 568 subjects 62...
Background FK506 binding protein 51 (FKBP51) is an Hsp90 co-chaperone and regulator of the glucocorticoid receptor, consequently stress physiology. Clinical studies suggest a genetic link between FKBP51 antidepressant response in mood disorders; however, underlying mechanisms remain elusive. The objective this study was to elucidate role actions antidepressants, with particular focus on pathways autophagy. Methods Findings Established cell lines, primary neural cells, human blood cells...
Genome-wide study in Germans identifies four novel multiple sclerosis risk genes and confirms already known gene loci.
Chaperone switching at the kinase CDK5 mediates epigenetic effects of antidepressants.
Abstract Background: Evidence suggests that cannabis use may be associated with suicidality in adolescence. Nevertheless, very few studies have assessed this association low- and middle-income countries (LMICs). In cross-sectional survey, we investigated the of suicidal attempts adolescents from 21 LMICs, adjusting for potential confounders. Method: Data Global school-based Student Health Survey was analyzed 86,254 [mean (SD) age = 13.7 (0.9) years; 49.0% girls]. Suicide during past year...
Abstract The pharmacological treatment of depression consists stages trial and error, with less than 40% patients achieving remission during first medication trial. However, in a large, randomized-controlled (RCT) the U.S. (“GUIDED”), significant improvements response rates were observed who received guided by combinatorial pharmacogenomic testing, compared to treatment-as-usual (TAU). Here we present results from Canadian “GAPP-MDD” RCT. This 52-week, 3-arm, multi-center, participant-...
Context: A consistent body of evidence supports a role reduced neurotrophic signaling in the pathophysiology major depressive disorder (MDD) and suicidal behavior.Especially suicide victims, lower postmortem brain messenger RNA protein levels neurotrophins their receptors have been reported.Objective: To determine whether brain-derived factor (BDNF) gene or its high-affinity receptor gene, tyrosine kinase 2 (NTRK2), confer risk for attempt (SA) MDD by investigating common genetic variants...
Abstract Major depressive disorder (MDD) is a common, complex psychiatric and leading cause of disability worldwide. Despite twin studies indicating its modest heritability (~30–40%), extensive heterogeneity genetic architecture have complicated efforts to detect associated risk variants. We combined single-nucleotide polymorphism (SNP) summary statistics from the CONVERGE PGC MDD, representing 10 502 Chinese (5282 cases 5220 controls) 18 663 European (9447 9215 subjects. determined fraction...